-
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例:华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势,细胞生物临床研究不断深化,伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成,生态圈的完善将在很大限度上推动产业快速发展。数据显示,中国细胞治疗企业融资金额不断增加,从2014年的0.2亿元增长至2019年的28.9亿元。其中,2018年中国细胞治疗企业融资额同比增长706.8%,呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇,同时也有挑战并存。后续产业的发展,将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局,企业也应积极开展生态合作以及更为密切关注市场需求动向,将疗法和新一代医疗创新技术深度融合,实现市场产品多元化与差异化,并推出独特性的精准治疗,从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:恒瑞医药,白云山,111集团,平安好医生,好大夫在线,优健康,春雨医生,微医,丁香医生,和美医疗,北大医疗,PHG,新氧,联合丽格,正广兴家庭医生,强森医疗,微脉,美中嘉和,零氪科技,中有精准医疗,思派网络,普瑞眼科,臻和科技,移宇科技,小鹿医馆,妈咪知道,八百方,京东医药,阿里健康大药房,1药网,一心堂,健一网,好药师,健客网,美丽神器,更美,悦美,美莱整形,伊美尔,丽都整形,芝星整形,欧华美科
大健康产业细分领域的垂直深化,推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响,2019年,大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示,受2018年和2019年上半年医疗领域负面舆情的影响,大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为,受社会医疗需求和国家政策的推动,大健康产业仍是未来投资的亮点。
The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies. -
艾媒报告|2019中国婴幼儿保育行业细分领域深度分析报告
本报告研究涉及企业/品牌/案例:华润万家、Ekoala、美国费雪公司、长春长生生物科技股份有限公司、拉克塔利斯集团、帮宝适、好奇、妙而舒、大王、MOONY、妈咪宝贝、安儿乐、雀氏、茵茵、爹地宝贝、露安适、DODIE、凯儿得乐、倍康、米菲、吉氏、一朵、纽诺教育、馨心教育、圣顿教育、袋鼠麻麻、多乐小熊、Urjoy school
中国的婴幼儿保育行业主要包括婴幼儿食品、用品、医疗、托育等领域。在婴幼儿食品领域,2019年,中国婴幼儿的辅食渗透率仅为25.0%左右,中国大陆婴幼儿的辅食和奶粉消费额的比例为1:7,中国港澳台地区为1:4,欧美等发达国家为1:1。在婴童用品领域,2018年中国婴儿推车市场规模达到132.1亿元,同比增长6.3%。63.9%的消费者计划在2019年增加消费支出,其中22.0%的消费者预计消费支出增加比例超过三成。在婴幼儿医疗领域,2018年,共有28种药品被要求修改说明书,包括一些中药注射剂、中成药大品种等。在婴幼儿照护领域,2019年5月,中国国务院发布了《国务院办公厅关于促进3岁以下婴幼儿照护服务发展的指导意见》,提出要大力推动婴幼儿照护行业发展,而2019年中国3岁以下婴幼儿在各类托育机构的入托率仅为4.1%,远远低于发达国家25%-55%的入托率。
China's infant and children care industry mainly includes infant food, supplies, medical care, and childcare. In the field of infant food, in 2019, the penetration rate of complementary food for infants and young children in China was only about 25.0%. Meanwhile, the ratio of food supplement and milk powder consumption for infants and toddlers in mainland China is 1:7, while in developed countries (Europe and the United States, etc.), the ratio is 1:1, and that in Hong Kong, Macao and Taiwan is 1:4. In the field of baby products, the size of China's baby stroller market reached 13.21 billion yuan in 2018, a year-on-year increase of 6.3%. 63.9% of consumers plan to increase consumer spending in 2019, with 22.0% of them expecting a 30% increase in consumer spending. In the field of infant and child medical care, in 2018, a total of 28 kinds of medicines were required to modify the instructions, including some Chinese medicine injections and large varieties of proprietary Chinese medicines. In the field of infant care, in May 2019, the State Council of China issued the “Guiding Opinions of the General Office of the State Council on Promoting the Development of Infant and Child Care Services Under 3 Years Old”, proposing to vigorously promote the development of infant care industry. China’s infants and young children have a 4.1% enrollment rate in various types of care institutions, far lower than the enrollment rate of 25%-55% in developed countries. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告